Echo IQ (EIQ) Q3 2026 TU earnings summary

Executive summary

• Achieved strong US commercial traction with EchoSolv AS, including deployment at Mount Sinai and a growing pipeline of over 50 active accounts across major hospital networks.

• Agreement with Mayo Clinic enables reselling and distribution of EchoSolv HF post-FDA clearance, expanding access to over 80 partner hospitals.

• Usage of EchoSolv AS increased by ~131% quarter-over-quarter, with 9,220 echocardiograms processed in Q1 CY26, indicating accelerating clinical adoption.

• Expanded US sales team with key regional appointments and dedicated implementation capability to support onboarding and retention.

• Advanced multi-condition platform strategy, with additional indications in development and strengthened IP portfolio through 10 new patent filings and four new trademarks.

Financial highlights

• Cash and cash equivalents at 31 March 2026 were $11.14m, down from $13.21m at 31 December 2025.

• Net cash used in operating activities for the quarter was $2.65m.

• Received $619k from equity securities issued during the quarter.

• Estimated quarters of funding available is 4.2, providing adequate runway for strategic priorities.

• $162k in payments made to related parties for director salaries and associated costs.

Outlook and guidance

• Near-term priorities include major US hospital group signings, FDA clearance for EchoSolv HF, and activation of heart failure reimbursement.

• Strategic partnerships and international expansion (EU/UK and Australia) are being pursued.

• Medium-term drivers include additional Tier-1 hospital contracts, system-wide rollouts, and product pipeline expansion.